Background: HIV infection is a major public health problem in sub-Saharan Africa, particularly in Burkina Faso. This study aimed to describe the socio-demographic characteristics of newly person living with HIV initiating antiretroviral treatment at the Adult Day Hospital of Bobo-Dioulasso over a five-year period. Materials and methods: A descriptive cross-sectional study was conducted from 1 January 2016 to 31 December 2020 at the Adult Day Hospital of Bobo-Dioulasso. People newly diagnosed with HIV after confirmatory testing and initiating antiretroviral therapy were included in this study.  

Tenofovir, alias (R)-PMPA, was first divulged as an anti- HIV agent in 1993 [1]. That it would in 2012, become the first antiretroviral agent, approved by the US FDA (Food and Drug Administration) to prevent HIV infection, could have been predicted from the findings of Tsai et al.

As the new editor-in-chief of Archives of Gastroenterology Research (AGR) I cordially welcome all current readers of AGR and future contributors to AGR. Together with my editorial team of AGR we encourage scientists and clinicians involved in the care of patients with gastrointestinal diseases to submit their interesting reports to AGR with the aim to be published following fair evaluation by external peer reviewers

We present two unique cases in which two HIV positive patients with generalized lymphadenopathy and pancytopenia without any skin lesions were diagnosed with primary lymph node Kaposi´s Sarcoma after excisional biopsy of an inguinal lymph node. 

Cellular components are attractive targets for antiviral therapy because they do not mutate as readily as do viral proteins do [1-3]. The identification of CCR₅ as an HIV-1 coreceptor [4-7], facilitated by the discovery of the antiviral activities of CCR₅ ligand ?-chemokines [8], resulted in the development of new viral entry inhibitors to block CCR₅ binding, including both- small molecules and CCR₅ antibodies